Recursion Pharmaceuticals is trading at $3.42, up 5.19%, mainly supported by biotech-sector strength.
- No new company-specific announcement was identified on August 25, 2026; the latest major update was second-quarter results released August 5.
- XBI rose 2.06% amid a broader risk-on session.
- Genentech neuroscience collaboration progress and lower operating-expense guidance remain supportive background, not new catalysts.